Angewandte
Chemie
Table 1: Relative binding affinity (RBA) values for the EDCs and reference compounds for ERa and ERb.
EDC or reference compound
I
II
III
IV
a
b
a
b
a
b
a
b
RBA[a]
3.8Æ0.8 3.6Æ 0.2
1.9Æ0.3 2.3Æ0.4
83–106%
0.9Æ0.1
3.3Æ0.5
2.9Æ0.2
2.8Æ0.3
2.4Æ0.3
10.3Æ0.4
(ERa)
RBA[a]
0.2Æ0.1
1.2Æ0.4
5.8Æ0.1 10.2Æ0.4
2.7Æ0.3
14.4Æ3.8
(ERb)
ligand–receptor access ratio[b]
nature of tether explanation
17–27%
long
60–104%
short
19–23%
short
medium; hydrophobic
ligand access restricted by
EDC aggregation
Good ligand–receptor ligand access restricted by encap- good ligand–receptor
access sulation by PAMAM and tether access
[a] RBA=relative binding affinity determined in competitive radiometric binding assays.[21,22] RBA={IC50[estradiol]/IC50[compound]}ꢀ100. Values are
the mean Æ range or SD of 2 or more independent experiments. The RBA for estradiol is 100; Kd value for estradiol is 0.2 nm for ERa and 0.5 nm for
ERb. [b] Ligand–receptor access ratio is defined as {RBA[EDC]/RBA[reference compound]}ꢀ100.
EDC IVa, with a moderate length but hydrophobic penta-
methylene group linker, is most likely the result of aggrega-
tion.
of the ligand to the receptor. Our findings hold important
implications for the future design of drug– or hormone–
polymer conjugates where receptor interaction by the poly-
mer-bound ligand is the goal, and our investigation provides
approaches that can be used to evaluate the behavior of new
ligand–polymer conjugates. We believe that these principles
will help ensure success in the future development of such
novel polymer-based biological reagents.
We determined the ligand access to the receptor in all four
EDCs by comparing their binding affinities for the estrogen
receptors with those of their reference compounds, which
were designed to mimic the EDC ligand in all respects except
not having the dendrimer attached (Scheme 1). Binding
affinities, determined by a known method,[21,22] are expressed
in Table 1 as relative binding affinity (RBA) values, where the
affinity of estradiol is set at 100. The values for the EDCs are
based on the ligand-equivalent concentration, which corrects
for the fact that multiple ligands are attached to each
dendrimer.
All of the compounds have RBA values in the range 0.2–
14.4. Most notably, the short-tether EDCs (Ia, IIIa) have
RBA values for the estrogen receptors (ERs) that are very
close to those of the corresponding model compounds (Ib and
IIIb). In contrast, both the long and moderate tether length
EDCs (IIa and IVa) have much lower affinities than the
reference compounds. The ratio of EDC to reference com-
pound affinity, expressed in percent, can be termed the
“ligand–receptor access index” and provides a direct mea-
surement of ligand access to the receptor. The two short-
tether EDCs Ia and IIIa have ligand–receptor access indices
of 83–106% and 60–104%, respectively, whereas the EDCs
with either long- or medium-length tethers (IIa and IVa) have
indices of only 17–27% and 19–23%, respectively. Thus, as
expected from the spectroscopic and hydrodynamic measure-
ment studies, the short-tether EDCs (Ia and IIIa) provide
much better ligand access to the receptor than do the longer
tether EDCs (IIa and IVa), for the reasons summarized in the
Table 1.
Received: May 15, 2006
Revised: August 24, 2006
Published online: October 6, 2006
Keywords: dendrimers · estrogen · hormones · receptors ·
.
solvent effects
[1] R. Esfand, D. A. Tomalia, Drug Discovery Today 2001, 6, 427.
[2] C. C. Lee, J. A. MacKay, J. H. Frechet, F. C. Szoka, Nat.
Biotechnol. 2005, 23, 1517.
[3] T. D. McCarthy, P. Karellas, S. A. Henderson, M. Giannis, D. F.
OꢀKeefe, G. Heery, J. R. Paull, B. R. Matthews, G. Holan, Mol.
Pharm. 2005, 2, 312.
[4] S. Svenson, D. A. Tomalia, Adv. Drug Delivery Rev. 2005, 57,
2106.
[5] T. P. Thomas, I. J. Majoros, A. Kotlyar, J. F. Kukowska-Latallo,
A. Bielinska, A. Myc, J. R. Baker, Jr., J. Med. Chem. 2005, 48,
3729.
[6] I. Lee, B. D. Athey, A. W. Wetzel, W. Meixner, J. R. J. Baker,
Macromolecules 2002, 35, 4510.
[7] P. K. Maiti, T. Cagin, G. Wang, W. A. I. Goddard, Macromole-
cules 2004, 37, 6236.
[8] W. Chen, D. A. Tomalia, J. L. Thomas, Macromolecules 2000, 33,
9196.
[9] W. R. Harrington, S. H. Kim, C. C. Funk, Z. Madak-Erdogan, R.
Schiff, J. A. Katzenellenbogen, B. S. Katzenellenbogen, Mol.
Endocrinol. 2006, 20, 491.
[10] P. E. Stevis, D. C. Deecher, L. Suhadolnik, L. M. Mallis, D. E.
Frail, Endocrinology 1999, 140, 5455.
[11] J. L. Temple, S. Wray, Endocrinology 2005, 146, 558.
[12] G. M. Anstead, K. E. Carlson, J. A. Katzenellenbogen, Steroids
1997, 62, 268.
[13] R. S. Muthyala, S. Sheng, K. E. Carlson, B. S. Katzenellenbogen,
J. A. Katzenellenbogen, J. Med. Chem. 2003, 46, 1589.
[14] S. Kannan, P. Kolhe, V. Raykova, M. Glibatec, R. M. Kannan, M.
Lieh-Lai, D. Bassett, J. Biomater. Sci. Polym. Ed. 2004, 15, 311.
[15] C. Kojima, K. Kono, K. Maruyama, T. Takagishi, Bioconjugate
Chem. 2000, 11, 910.
We have shown that tethering ligands to polymeric
macromolecules can significantly affect ligand access to a
receptor. In our EDCs, where the ligand is hydrophobic (for
example, an estrogen) and is attached to a macromolecule
having a flexible structure with surface invaginations (for
example, PAMAM), ligand access becomes a function of the
tether: Short-tether EDCs are able to maintain ligand
exposure, thus providing essentially unimpeded access to
the ERs; in contrast, ligands attached through long or
hydrophobic tethers experience masking by burrowing into
the PAMAM or by aggregation and thus result in poor access
Angew. Chem. Int. Ed. 2006, 45, 7243 –7248
ꢀ 2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
7247